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Abstract
Introduction The aim of this study was to compare
cardiovascular autonomic nervous system function in patients
with primary Sjögren's syndrome (pSS) with that in control
individuals, and to correlate the findings with autonomic
symptoms and the presence of exocrine secretory dysfunction.
Methods Twenty-seven female patients with pSS and 25
control individuals completed the COMPASS (Composite
Autonomic Symptom Scale) self-reported autonomic symptom
questionnaire. Beat-to-beat heart rate and blood pressure data
in response to five standard cardiovascular reflex tests were
digitally recorded using a noninvasive finger pressure cuff and
heart rate variability was analyzed by Fourier spectral analysis.
Analysis was performed by analysis of variance (ANOVA),
multivariate ANOVA and repeated measures ANOVA, as
indicated. Factor analysis was utilized to detect relationships
between positive autonomic symptoms in pSS patients.
Results Multiple, mild autonomic disturbances were observed
in pSS patients relating to decreased heart rate variability,
decreased blood pressure variability and increased heart rate,
which were most evident in response to postural change. There
was a strong trend toward an association between decreased
heart rate variability and increased severity of the secretomotor,
orthostatic, bladder, gastroparesis and constipation self-
reported autonomic symptom cluster identified in pSS patients.
This symptom cluster was also associated with fatigue and
reduced unstimulated salivary flow, and therefore may be an
important component of the clinical spectrum of this disease.
Conclusion There was evidence of mild autonomic dysfunction
in pSS as measured with both cardiovascular reflex testing and
self-reported symptoms. Pathogenic autoantibodies targeting
M3 muscarinic receptors remain a strong candidate for the
underlying pathophysiology, but practical assays for the
detection of this autoantibody remain elusive.
Introduction
Primary Sjögren's syndrome (pSS) is a systemic autoimmune
disease that is characterized by exocrine failure of salivary and
lacrimal glands, in addition to a wide range of extraglandular
features. Many clinical features of pSS are also features of
autonomic neuropathy, which has been documented in pSS
[1]. Functional autoantibodies that target muscarinic acetyl-
choline receptors have been identified in the sera of patients
with pSS, and these may represent an important mechanism
in the production of sicca symptoms, bladder irritability and
gastrointestinal symptoms [2,3]. Cardiovascular autonomic
responses are a validated measure of autonomic nervous sys-
tem function, and analysis of heart rate variability (HRV) pro-
vides additional information about parasympathetic and
sympathetic activity. Studies in this area have yielded variable
results in pSS patients, depending on the population studied
and methodology applied. Some reported no autonomic dys-
function [4,5] whereas others found disturbance of the
ANOVA= analysis of variance; COMPASS = Composite Autonomic Symptom Scale; FACIT-F = Functional Assessment of Chronic Illness Therapy-
Fatigue; HRV = heart rate variability; LF = low frequency; M3R = type 3 muscarinic receptor; MBP = mean blood pressure; MET = multiples of resting 
metabolic state; pNN50 = the proportion of successive RR intervals differing by more than 50 ms; pSS = primary Sjögren's syndrome; RMSSD = 
standard deviation of the differenced RR interval series; SBP = systolic blood pressure; SDNN = standard deviation of the RR interval series.Arthritis Research & Therapy    Vol 10 No 2    Cai et al.
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parasympathetic system [6,7] or both parasympathetic and
sympathetic nervous systems [8-10]. The aim of this study was
to compare objectively autonomic nervous system function in
pSS patients with that in control individuals, and to correlate




Female pSS patients were recruited consecutively from the
Rheumatology Clinic at The Queen Elizabeth Hospital. All
patients met the revised 2002 American European Consensus
criteria [11] for pSS. Age-matched, population-based female
control individuals were recruited from the local community.
Exclusion criteria for the study included diabetes, ischaemic
heart disease, current anticholinergic medication, or a serious
medical illness. Seven participants from each group were tak-
ing antihypertensive medications, which were withheld for 24
hours before testing. Classes of medications used by pSS
patients and control individuals (respectively) were as follows:
angiotensin-converting enzyme inhibitors (one and two partic-
ipants),  β-blockers (one and two participants), angiotensin
receptor blockers (three and four participants), diuretics (two
and three participants), calcium channel blockers (three and
no participants) and hydrallazine (one and no participants).
Five pSS patients were using pilocarpine, which was withheld
for 24 hours before testing. Two control individuals in whom
cardiac arrhythmias were detected during cardiovascular
reflex testing were excluded from the analysis, and 27 pSS
patients and 25 control individuals were included in the final
study.
Eighteen (67%) of the pSS patient sera were positive for Ro/
La autoantibodies, and of those tested nine out of nine (100%)
were negative for cryoglobulins and two out of 17 (12%) had
low C3 or C4 levels. Eleven patients (41%) had Raynaud's
phenomenon, and of those tested 13 out of 14 (93%) had a
positive labial salivary gland biopsy. The average age of onset
of disease was 48 years (range 29 to 73 years) and the aver-
age disease duration was 13 years (range 2 to 29 years).
All participants gave informed, written consent for the study,
and the study was approved by the North Western Adelaide
Health Service Ethics of Human Research Committee.
Study protocol
All testing was conducted in the morning and in a standardized
manner. Hypertensive medications were withheld 24 hours
before testing, participants abstained from caffeine and ciga-
rettes from the previous evening, and artificial tears from wak-
ing that morning. Patients were instructed to have an early light
breakfast, and testing did not commence until the patients had
been fasting for more than 1 hour.
Participants initially completed the FACIT-F (Functional
Assessment of Chronic Illness Therapy-Fatigue), a 13-item
assessment of fatigue [12], and the COMPASS (Composite
Autonomic Symptom Scale) questionnaire [13]. A 15-minute
unstimulated whole salivary flow and Schirmer's-I test were
performed as objective measures of dryness. Sicca was
defined as an unstimulated salivary flow test of under 1.5 ml in
15 minutes and/or a Schirmer's test with under 5 mm wetting
in both eyes over 5 minutes.
Physical activity levels were measured using the short tele-
phone form of the International Physical Activity Questionnaire
[14]. Participants were classified as HEPA (health enhancing
physical activity) active if they achieved either of the following:
activity of vigorous intensity on at least 3 days, achieving a min-
imum of at least 1,500 multiples of resting metabolic state
(MET)-minutes/week; or 7 or more days of any combination of
walking, or activity of moderate intensity or vigorous intensity
achieving a minimum of at least 3,000 MET-minutes/week. All
study participants were examined by a neurologist. Abnormal-
ities were observed in five pSS patients: bilateral carpal tunnel
syndrome (in one patient), an old minor cerebrovascular acci-
dent (in one), unilateral benign essential tremor (in one),
peripheral neuropathy (in two) and facial numbness (in one).
Cardiovascular reflex testing
Noninvasive, beat-to-beat measurements of systolic blood
pressure (SBP), diastolic blood pressure, mean blood pres-
sure (MBP), heart rate and heart period (RR interval) were
recorded during all manoeuvres using the Finapres™ (Ohm-
eda. Louisville, Colorado, USA) finger arterial pressure moni-
toring system [15].
Manoeuvres (described below) were performed in the follow-
ing order: supine rest, postural change, Valsalva manoeuvre
(seated), isometric grip (seated) and controlled breathing
(seated). Participants rested for several minutes between suc-
cessive manoeuvres and between replicates of manoeuvres.
Supine rest
Participants lay quietly on a bed, and once settled recording
commenced for a period of 5 minutes. Brachial blood pressure
was measured using a digital blood pressure monitor approxi-
mately 1 minute before completion of this period.
Postural change
Participants were asked to stand quickly and remain standing
quietly for a period of 6 minutes. Brachial blood pressure was
measured with a digital blood pressure monitor at 2 and 5 min-
utes after standing.
Valsalva manoeuvre (seated)
Participants blew into a closed tube with a small leak, main-
taining an expiratory pressure of 40 mmHg for 10 seconds.
Beat-to-beat measurements were monitored for a period of 1Available online http://arthritis-research.com/content/10/2/R31
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minute after release of expiratory pressure. This manoeuvre
was performed three times.
Isometric grip (seated)
Patients gripped a dynamometer for 3 minutes, maintaining a
contraction pressure of one-third of their maximum voluntary
contraction pressure.
Controlled breathing (seated)
Participants maintained a controlled, even breathing rate of six
breaths/minute over a period of 1 minute. This manoeuvre was
performed three times.
Cardiovascular reflex test analysis
Five standard parameters of the cardiovascular autonomic test
were estimated [16]: supine to standing ΔSBP, supine to
standing 30/15 ratio, isometric grip ΔMBP, Valsalva ratio, and
breathing E/I ratio.
Supine to standing ΔSBP
The supine to standing ΔSBP was calculated as the brachial
SBP 5 minutes after standing minus the supine brachial SBP.
Supine to standing 30/15 ratio
The supine to standing 30/15 ratio is the ratio of the longest
RR interval near to the 30th beat after standing to the shortest
RR interval near to the 15th beat after standing.
Isometric grip ΔMBP
The isometric grip ΔMBP is the MBP (Finapres™; Ohmeda) at
the end of the 3-minute grip period minus the MBP just before
commencing grip.
Valsalva ratio
The Valsalva ratio is the ratio of the longest RR interval imme-
diately after strain to the shortest RR interval during strain. The
geometric mean was estimated from three replicates.
Breathing E/I ratio
The breathing E/I ratio is the mean of the longest RR intervals
during each expiration divided by the mean of the shortest RR
intervals during each inspiration [17]. The geometric mean
was estimated from three replicates.
Heart rate variability analysis
Time domain analysis
The mean and time domain HRV parameters of the RR interval
[18], including the standard deviation (SDNN), the proportion
of successive intervals differing by more than 50 ms (pNN50)
and the standard deviation of the differenced RR series
(RMSSD), were calculated for both supine and standing
(beginning 1 minute after standing) positions over a 5-minute
recording interval.
Frequency domain (spectral) analysis
Cross-spectral analysis of the beat-to-beat RR and SBP data
was performed on both supine and standing 5-minute record-
ing intervals. The data were interpolated at a frequency of 2 Hz
using cubic spline interpolation. Exact length cross-spectral
Fourier analysis was performed using the Time Series module
of Statistica (v6.1; Statsoft Inc., Tulsa, Oklahoma, USA), with
a taper of 15% and a Hamming window of width five to esti-
mate the spectral densities. Power was calculated by integra-
tion of the spectral densities over the frequency ranges of 0.04
to 0.15 Hz (low frequency [LF]) and 0.15 to 0.4 Hz (high fre-
quency). The gain, essentially a regression coefficient for the
SBP variability as a predictor of RR variability, was used as a
measure of baroreflex function [19]. This was estimated as the
total cross-amplitude power divided by the total SBP power
over the relevant frequency range.
Statistical analysis
The cardiovascular reflex test scores were analyzed as contin-
uous variables rather than classified as normal, borderline and
abnormal, as initially described [16]. This is because there was
a substantial age dependence in these scores, also recog-
nized in other studies [20], that is not incorporated into the
classification criteria. All analyses were performed by analysis
of variance (ANOVA), multivariate ANOVA and repeated
measures ANOVA, as indicated. With the exception of blood
pressure, measurements of autonomic function and HRV,
which were either ratios or rate measurements, were log-trans-
formed before analysis to normalize their distribution.
Reported results are for an age-unadjusted analysis, but they
did not differ from results for an age-adjusted analysis. Many
of the cardiovascular reflex test and COMPASS domain
scores were highly correlated with each other. Therefore prin-
cipal component factor analysis was employed to detect struc-
ture in the relationships between parameters. All factors with
a minimum Eigan value of 1 were extracted. All analyses were
performed using Statistica (v6.1; Statsoft Inc.).
Results
Baseline characteristics
All study participants were female and their baseline charac-
teristics are shown in Table 1. pSS patients and control indi-
viduals were well matched in terms of age. Physical activity
level, SBP, hypertension and prior smoking history were simi-
lar between groups. As expected, there was a higher inci-
dence of objective sicca symptoms in pSS patients, measured
just before autonomic testing, and more severe fatigue.
COMPASS scores
Self-reported autonomic symptoms, as assessed using the
COMPASS score (Table 2), were increased in pSS patient
relative to control individuals (34.2 versus 15.3; P = 0.0002).
These scores are consistent with normal autonomic function in
control individuals and mild to moderate symptom severity in
pSS patients when interpreted against COMPASS validationArthritis Research & Therapy    Vol 10 No 2    Cai et al.
Page 4 of 10
(page number not for citation purposes)
scores of 9.8 (± 9) for control individuals, 25.9 (± 17.9) for
patients with nonautonomic peripheral neuropathy, and 52.3
(± 24.2) for patients with autonomic failure [13]. The under-
statement scores were modest and comparable between pSS
patients and control individuals. pSS patients scored higher in
the psychosomatic component (mean 0.60 versus 0 out of a
maximum score of 10; P = 0.006; Table 2). However, these
scores were in fact low and primarily attributable to pSS
patients reporting difficulty in swallowing, which is a compo-
nent of the COMPASS psychosomatic score but also a com-
mon symptom of pSS associated with dry mouth.
When analyzed by symptom subscale (Table 2), the most sub-
stantive difference between pSS patients and control individ-
uals was the secretomotor subscale scores, as expected.
There was also evidence of bladder dysfunction, as we
Table 1
Baseline characteristics of pSS patients and control individuals
pSS patients Control individuals P
Number of participants (all female) 27 25
Age (years; range) 60 (40–79) 60 (42–79) 0.98
Supine brachial SBP (mmHg [95% confidence interval]) 131 (124 to 138) 134 (127 to 141) 0.53
Hypertension diagnosis (n/n [%]) 7/27 (26%) 10/25 (40%) 0.43
Prior smokersa (n/n [%]) 9/27 (33%) 10/25 (40%) 0.83
HEPA activeb (n/n [%]) 8/25 (32%) 9/25 (36%) 1.0
FACIT-F score (standard error) 20.6 (2.6) 10.0 (2.0) 0.002
Siccac (n/n [%]) 22/26 (85%) 5/25 (20%) 0.00001
aNone of the participants were current smokers. bHEPA (Health Enhancing Physical Activity) active is the highest physical activity level, as 
measured using the International Physical Activity Questionnaire. cSicca was defined as an unstimulated salivary flow test of under 1.5 ml in 15 
minutes and/or a Schirmer's test with under 5 mm wetting in both eyes. FACIT-F, Functional Assessment of Chronic Illness Therapy-Fatigue; pSS, 
primary Sjögren's syndrome; SBP, systolic blood pressure.
Table 2
COMPASS scores in pSS patients versus control individuals
Mean (95% CI)
COMPASS score Maximum score pSS patients Control individuals P
Subscale
Orthostatic intolerance 40 10.2 (7.4 to 13.9) 4.5 (2.1 to 9.4) 0.029*
Bladder disorder 20 4.7 (3.5 to 6.3) 1.8 (0.8 to 4.0) 0.007*
Diarrhoea 20 3.0 (1.9 to 4.7) 1.1 (0.3 to 4.0) 0.07
Gastroparesis 10 1.2 (0.8 to 2.0) 0.5 (0.1 to 1.7) 0.08
Secretomotor disorder 20 6.8 (5.8 to 8.1) 2.4 (1.5 to 3.9) 0.000002*
Sleep disorder 15 2.2 (1.6 to 3.0) 1.5 (0.9 to 2.5) 0.23
Constipation 10 0.7 (0.3 to 1.7) 1.4 (0.9 to 2.2) 0.10
Vasomotor 10 2.9 (2.1 to 4.0) 0.6 (0.1 to 3.1) 0.002*
Pupillomotor impairment 5 1.9 (1.5 to 2.3) 1.2 (0.9 to 1.7) 0.02*
Syncope 20 0.6 (0.3 to 1.2) 0.2 (0.1 to 2.7) 0.18
COMPASS Total 170 34.2 (28.2 to 41.3) 15.3 (9.8 to 23.8) 0.0002*
Understatement 10 2.28 (1.22 to 3.35) 2.56 (1.57 to 3.55) 0.70
Psychosomatic 10 0.60 (0.24 to 1.06) 0 0.006*
*Statistically significant finding (P < 0.05). CI, confidence interval; COMPASS, Composite Autonomic Symptom Scale; pSS, primary Sjögren's 
syndrome.Available online http://arthritis-research.com/content/10/2/R31
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previously reported [21], in addition to orthostatic intolerance,
and vasomotor and pupillomotor dysfunction.
There were multiple correlations between the COMPASS
symptom subscales, and factor analysis was employed to ana-
lyze clustering of symptoms within pSS patients. Within pSS
patients, four independent factors were extracted that
accounted for 73% of the total variance. The secretomotor
subscale had substantial factor loadings for both factor 1
(24% variance), for which additional high loadings were
observed for orthostatic, bladder, constipation and gas-
troparesis subscales; and factor 2 (15% variance), which had
an additional high loading on the pupillomotor subscale (Fig-
ure 1a). Factor 3 (22% variance) had substantial loadings on
vasomotor, gastroparesis and syncope subscales, whereas
factor 4 (12% variance) had substantial negative loadings on
diarrhoea and sleep subscales. Importantly, factor 1 scores for
each patient were associated with both objective sicca, as
measured by 15-minute unstimulated salivary flow (P = 0.025,
Figure 1b), and the FACIT-F scores (Spearman rank correla-
tion coefficient 0.42; P = 0.035; Figure 1c). Therefore, auto-
nomic dysfunction is a component of pSS and manifests in
symptoms additional to secretory dysfunction. There were no
associations (P = 0.40 and P = 0.18, respectively) with factor
2 scores, which may be interpreted as measures of parasym-
pathetic function. Furthermore, there were no associations
with Ro/La autoantibody status or Raynaud's phenomenon.
Standard cardiovascular autonomic tests
There were significant differences between pSS patients and
control individuals in the five standard measures of cardiovas-
cular autonomic testing (multivariate P = 0.018, Table 3). Indi-
vidually significant differences were specifically related to
postural change. There was both an attenuated increase in
brachial ΔSBP (P = 0.031) and an attenuation in the RR 30/
15 ratio (P = 0.001) in response to standing in pSS patients.
There was no evidence of any differences in the Valsalva ratio,
MBP response to isometric grip, or E/I ratio during controlled
breathing.
The brachial SBP response to standing was further analyzed
at both 2 and 5 minutes after standing. The difference in ΔSBP
(Table 3) between pSS patients and control individuals can be
traced to a decline in SBP between 2 and 5 minutes standing
in pSS patients, as compared with a relative increase in the
same time period in control individuals (Figure 2a). Two pSS
patients had to be seated before completion of the standing
exercise (and were therefore excluded from this component of
the analysis) because they exhibited symptoms of postural
Figure 1
Factor analysis of COMPASS autonomic symptom scale scores within pSS patients Factor analysis of COMPASS autonomic symptom scale scores within pSS patients. (a) Scatterplot of rotated (varimax normalized) COMPASS 
subscale factor loadings for factor 1 (24% of total variance) and factor 2 (15% of total variance), both with appreciable loadings for the secretomo-
tor subscale. Factor 1 had the highest loadings for secretomotor, orthostatic, gastroparesis, constipation and bladder subscales, which is indicative 
of a substantial clustering of these symptoms within patients who have primary Sjögren's syndrome (pSS). The highest loadings for factor 2 were 
observed with both the secretomotor and pupillomotor subscales. (b) Scatterplot of the COMPASS factor 1 scores for each pSS patient by results 
of the contemporaneous 15-minute unstimulated salivary flow test. The horizontal bars represent mean scores for each group. Factor 1 scores were 
significantly higher in patients with this objective measure of dryness (P = 0.025), whereas factor 2 scores were not (P = 0.40; data not shown). 
Scatterplot of the COMPASS factor 1 scores for each pSS patient by the FACIT-F scores. Factor 1 scores were significantly correlated with fatigue 
scores (P = 0.035), whereas factor 2 scores were not (P = 0.18; data not shown). COMPASS, Composite Autonomic Symptom Scale; FACIT-F, 
Functional Assessment of Chronic Illness Therapy-Fatigue.Arthritis Research & Therapy    Vol 10 No 2    Cai et al.
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hypotension such as dizziness and nausea associated with a
decline in blood pressure.
Although the observed differences in the ΔSBP and standing
RR 30/15 ratio between pSS patients and control individuals
are consistent with some orthostatic intolerance in pSS, also
observed in the COMPASS subscale scores (Table 2), the
magnitude of these differences is relatively modest and the val-
ues are within the normal range [16]. This suggests the pres-
ence of mild, possibly subclinical autonomic dysfunction in
pSS.
Heart rate variability: time domain measures
There was a relative tachycardia in pSS patients (Figure 2b) as
assessed by repeated measures ANOVA for both supine and
standing positions. This relative tachycardia was most pro-
nounced during standing (P = 0.039), but there was no evi-
dence that the decrease in RR intervals associated with
postural change was different between patients and control
individuals (P = 0.21, by repeated measures ANOVA). The
mean standing RR intervals in pSS patients was 688 ms (95%
confidence interval 670 ms to 755 ms), as compared with 781
ms (95% confidence interval 735 ms to 828 ms) in control
individuals.
Standard time domain estimates of HRV include SDNN,
RMSSD and pNN50 [18]. There was a trend toward
decreased HRV in pSS relative to control individuals in all
three measures, but only the pNN50 frequency was significant
(P  = 0.025; Figure 2c). There was no evidence that the
decrease in pNN50 associated with postural change was dif-
ferent between patients and control individuals (P  = 0.94,
repeated measures ANOVA).
Heart rate variability: spectral analysis
There were differences in the spectral (or power) analysis
between pSS patients and control individuals, predominantly
in the LF power range, in response to standing. The normal
SBP variability response to standing is an increase in LF
power. This was significantly attenuated in pSS patients (P =
0.01; Figure 2d). Parasympathetic withdrawal upon standing
results in a decrease in HRV. In the LF domain this is counter-
balanced by increased LF blood pressure variability, and the
net result of a normal response to standing is little change in
LF HRV. In control individuals there was minimal change in LF
HRV in response to standing, which is consistent with a nor-
mal response. However, in pSS there was a substantial
decrease in LF HRV (P = 0.024; Figure 2e). There were no dif-
ferences in the baroreflex function, as estimated by the cross-
spectral LF gain (data not shown).
Factor analysis of cardiovascular autonomic indices
RR intervals, LF RR power (HRVLF), pNN50, change in SBP
on standing (ΔSBP), LF SBP power and the 30/15 ratio were
all decreased in pSS patients relative to control individuals on
standing. Because there were multiple correlations between
these indices, factor analysis was again employed for pSS
patient data to detect clustering or structural relationships
between these indices and enhance interpretation. Three
independent factors (Figure 3a) were extracted, which
accounted for 75% of the total variance, and this is indicative
of multiple autonomic abnormalities in pSS patients. Factor 1
(33% variance) had the highest loadings for HRVLF, pNN50
and the 30/15 RR ratio, and may be interpreted as a HRV fac-
tor, possibly reflecting sympathetic/parasympathetic balance.
Interestingly, factor 1 scores were higher (less abnormal) in
patients with Raynaud's phenomenon (P = 0.025; Figure 3b)
which is associated with sympathetic overactivity [22]. Fur-
thermore, there was a modest correlation with the COMPASS
autonomic symptom factor 1, which did not quite reach statis-
tical significance (P = 0.08; Figure 3c). Factor 2 (22% vari-
ance) had the highest loadings for blood pressure variability
(ΔSBP and LF SBP power). Factor 3 (20% variance) had the
highest loading for heart rate (RR intervals). There was no rela-
tionship between these cardiovascular factors and Ro/La
autoantibodies, objective sicca measures, or fatigue scores.
Table 3
Cardiovascular autonomic tests in pSS patients versus control individuals
Mean (95% CI)
Cardiovascular autonomic test pSS patients Control individuals P
Supine to standing: ΔSBP +2 (-2 to +6) 9 (4 to 14) 0.031*
Supine to standing: 30/15 ratio 1.19 (1.14 to 1.24) 1.33 (1.27 to 1.40) 0.001*
Isometric grip: ΔMBP 22 (17 to 27) 27 (3 to 21) 0.24
Valsalva ratio 1.25 (1.18 to 1.33) 1.31 (1.25 to 1.37) 0.23
Breathing E/I ratio 1.17 (1.14 to 1.20) 1.18 (1.15 to 1.21) 0.66
Multivariate P value = 0.018
CI, confidence interval; ΔMBP, change in Finapres™ mean blood pressure (end of grip minus before grip); ΔSBP, change in brachial systolic blood 
pressure (5 minutes standing minus supine); pSS, primary Sjögren's syndrome.Available online http://arthritis-research.com/content/10/2/R31
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Discussion
In this study we demonstrated evidence, obtained from both
self-reported symptoms and objective cardiovascular reflex
testing, of mild autonomic dysfunction in pSS. From the cardi-
ovascular reflex testing, there was evidence of multiple auto-
nomic disturbances in pSS relating to decreased HRV,
decreased blood pressure variability and an increased heart
rate (tachycardia), which were most evident in response to
postural change. There was a strong trend toward an associ-
ation between decreased HRV and increased severity of the
Figure 2
Abnormal HRV responses after postural change in pSS patients Abnormal HRV responses after postural change in pSS patients. All analyses were performed by repeated measures analysis of variance. (a) Bra-
chial systolic blood pressure (SBP). The initial SBP response to standing was normal in patients who have primary Sjögren's syndrome (pSS). How-
ever, between 2 and 5 minutes after standing, there was a relative decline in SBP in pSS patients and a relative increase in control individuals (P = 
0.015). (b) RR intervals. There was a relative tachycardia in pSS patients. This was most pronounced during standing (P = 0.039). (c) The propor-
tion of successive RR intervals differing by more than 50 ms (pNN50) was lower in pSS patients than in control individuals over both postural posi-
tions (P = 0.025). (d) SBP power. The normal response to standing is an increase in SBP power, most evident in the low frequency (0.04 to 0.15 
Hz) domain. This was significantly attenuated in pSS patients (P = 0.01). (e) RR power. Parasympathetic withdrawal upon standing results in a 
decrease in heart rate variability (HRV). In the low frequency (LF) domain, this is counterbalanced by an increase associated with increased LF blood 
pressure variability (see panel c). The net result of a normal response to standing is very little change in LF HRV and a substantial decrease in high 
frequency HRV. In control individuals, there was minimal change in LF HRV in response to standing, consistent with a normal response. However, in 
pSS there was a substantial decrease in LF HRV upon standing, and therefore standing LF HRV was significantly lower in pSS patients (P = 0.024).Arthritis Research & Therapy    Vol 10 No 2    Cai et al.
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secretomotor, orthostatic, bladder, gastroparesis and consti-
pation self-reported symptom cluster in pSS patients. This
symptom cluster was also associated with fatigue and
reduced unstimulated salivary flow, and therefore may be an
important component of the clinical spectrum of this disease.
Of note, we [21] and others [23] previously reported
increased bladder symptoms in pSS patients; furthermore, a
high frequency of both delayed gastric emptying and
decreased bladder detrusor muscle tone has also been
observed in pSS patients [24].
Previous studies addressing cardiovascular autonomic func-
tion in pSS have yielded conflicting results, although a pattern
is emerging. Two studies using 24-hour Holter monitoring
[4,5], which reflects tonic balance, both reported negative
results. In contrast, a number of studies of provoked cardiovas-
cular responses or short-term HRV [6-10,25-27] identified
abnormalities in pSS, although not all of these were controlled
studies or used appropriate age-adjusted criteria for interpre-
tation of abnormal test results. Four controlled studies [8-
10,27] found abnormalities in either the 30/15 ratio or blood
pressure response to postural challenge, as we also observed,
and two controlled studies [6,26] identified reduced HRV/
blood pressure variability in pSS patients by using spectral
analysis. Our observation of a relative tachycardia in pSS
patients has not previously been reported. Four studies [8-
10,27] also reported a decreased breathing E/I ratio in pSS
patients, which we did not observe. However, this test is also
influenced by breathing tidal volume, which may have differed
between study participants and potentially confounded the
results. Similar to other studies [10], we did not observe an
association between cardiovascular reflex test scores and
objective measures of sicca in pSS patients, but this is the first
study to both examine and report an association between
objective measures of sicca and self-reported autonomic
symptoms in pSS patients.
Potential mechanisms of autonomic dysfunction in SS include
T-cell infiltration and destruction of ganglions and nerves [28],
cytokine-induced inhibition of neuropeptide secretion from
nerve endings [29], immune complex-mediated inflammation
(although few pSS patients in this study exhibited cryoglobu-
lins and/or low C3 or C4, which might indicate immune com-
plex deposition), and pathogenic autoantibodies targeting
receptors relevant for autonomic functioning [30]. IgG
autoantibodies, which inhibit the function of type 3 muscarinic
receptors (M3Rs), have been described in pSS patients
[3,31]. Importantly, these autoantibodies inhibit salivary secre-
tion [32], bladder detrusor muscle contraction [3], and colon
contractions [33]in vitro. Evidence that lower urinary tract
symptoms in pSS are autoantibody mediated comes from pas-
sive transfer of SS immunoglobulin or rabbit anti-M3R to mice,
Figure 3
Factor analysis of abnormal postural change cardiovascular autonomic indices within pSS patients Factor analysis of abnormal postural change cardiovascular autonomic indices within pSS patients. RR intervals, low frequency RR power (HRVLF), 
proportion of successive RR intervals differing by more than 50 ms (pNN50), change in systolic blood pressure on standing (ΔSBP), low frequency 
systolic blood pressure power (BPVLF) and the 30/15 ratio were all decreased in patients who have primary Sjögren's syndrome (pSS) relative to 
control individuals on standing. (a) Three-dimensional scatterplot of rotated (varimax normalized) factor loadings. Factor 1 had the highest loadings 
for HRVLF, pNN50 and the 30/15 RR ratio. Factor 2 had the highest loadings for ΔSBP and BPVLF. Factor 3 had the highest loading for RR intervals 
during standing. (b) Scatterplot of the HRV factor 1 scores for each pSS patient by the presence of Raynaud's phenomenon. The horizontal bars 
represent mean scores for each group. Factor 1 scores were significantly lower (more abnormal) in patients without Raynaud's (P = 0.025). (c) 
Scatterplot of the HRV factor 1 scores (y-axis) versus COMPASS factor 1 scores (x-axis) for each pSS patient. There was a negative correlation that 
did not quite reach statistical significance (P = 0.08).Available online http://arthritis-research.com/content/10/2/R31
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which produces the phenotype of overactive bladder [2]. Fur-
thermore, neutralization of anti-M3R autoantibodies by
intravenous immunoglobulin led to improvement in bladder
and bowel autonomic symptoms in patients with autoimmune
diseases [34]. Therefore, pathogenic M3R autoantibodies are
strongly implicated in the pathophysiology of the cluster of
secretomotor, bladder, gastroparesis, constipation and ortho-
static autonomic symptoms in pSS patients observed in the
present study.
Pathogenic M3R autoantibodies may also potentially influence
cardiovascular autonomic responses. Although the M2R sub-
type is the numerically and functionally predominant mus-
carinic receptor in the heart, recent studies have provided
compelling and solid evidence in support of the important
roles of M3R in regulating and maintaining cardiac function
and heart disease [35]. Furthermore, given the close structural
similarity between the M2R and M3R, it is likely that the
autoantibodies may be cross-reactive.
Muscarinic receptor-mediated cardiac parasympathetic activ-
ity is essential for regulating heart rate [35] and HRV [36]. Fur-
thermore, vasodilatory responses to cholinergic stimuli are
diminished in M3R knockout mice [37] and in pSS patients
[38], which may – at least in part – underpin the reduced
blood pressure variability observed in the present study. Car-
diovascular reflex tests are traditionally interpreted as an indi-
cation of parasympathetic or sympathetic function, but our
results are better interpreted as multiple autonomic distur-
bances in pSS relating to decreased HRV, decreased blood
pressure variability and increased heart rate, which are likely to
reflect a disturbance of parasympathetic/sympathetic balance.
Conclusion
We have confirmed the presence of mild autonomic dysfunc-
tion in pSS patients, as measured by both self-reported symp-
toms and objective assessment. We have identified an
important cluster of self-reported secretomotor, orthostatic,
bladder, gastroparesis and constipation symptoms in pSS,
which correlate with increased fatigue and reduced serum sal-
ivary flow. Cardiovascular reflex testing reveals multiple abnor-
malities that reflect probable disturbance of parasympathetic/
sympathetic balance. Although pathogenic M3R autoantibod-
ies remain a strong candidate for the underlying pathophysiol-
ogy in pSS, it is not yet possible to test this hypothesis,
because practical assays for anti-M3R autoantibody detection
remain elusive.
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